Trial Profile
A Randomized, Double Blind, Placebo Controlled Detrol LA 'Add-On' To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Pfizer; Viatris Inc
- 27 Oct 2009 New trial record.
- 01 Sep 2009 Primary endpoint 'Patient assessment of efficacy' has not been met.
- 01 Sep 2009 Results published in European Urology.